IL-13 protects epithelial cells from SARS-CoV-2 infection by inhibiting ACE2-mediated virus binding and cell entry
ImmunoHorizons · 2025
DOI: 10.1093/immhor/vlaf056 ↗Kurz gefasst
Fachartikel in der Zeitschrift ImmunoHorizons, 2025. Verfasst von Vadim Pivniouk und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cellular and Molecular Medicine, The University of Arizona, Tucson, AZ 85721, United States. Hauptthemen laut MEDLINE: Interleukin-13, Angiotensin-Converting Enzyme 2, SARS-CoV-2, COVID-19. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIAID NIH HHS, NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) preferentially infects airway epithelial cells. This infection is mediated by the binding of SARS-CoV-2 spike (S) protein to ACE2 expressed on target cells. Patients with allergic (type-2) asthma have been reported to be less susceptible to coronavirus disease 2019 (COVID-19), but these effects are controversial and mechanistically unclear. We previously showed lower expression of ACE2 mRNA in airway epithelial cells from type-2 asthmatics compared to healthy donors. Moreover, we and others demonstrated that the type-2 cytokine interleukin 13 (IL-13) suppresses ACE2 expression and SARS-CoV-2 infection in human epithelial cells. To better understand the relationship between type-2 inflammation, ACE2 expression, and SARS-CoV-2 infection, we investigated the effects of IL-13 on critical steps of epithelial cell infection by SARS-CoV-2: S protein-mediated binding to ACE2 on epithelial cells, and ACE2-mediated SARS-CoV-2 entry into these cells. Recombinant IL-13 significantly inhibited both these processes. This inhibition appeared to be mediated by IL-13-induced suppression of ACE2 transcription because IL-13 failed to affect S protein-mediated viral entry into cells that express ACE2 under the control of an IL-13 unresponsive heterologous promoter. We propose that IL-13 protects epithelial cells from SARS-CoV-2 infection largely by inhibiting ACE2 expression and ACE2-mediated downstream events that allow the virus to access its cellular targets.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cellular and Molecular Medicine, The University of Arizona, Tucson, AZ 85721, United States.
- Asthma and Airway Disease Research Center, The University of Arizona, Tucson, AZ 85721, United States.
- The BIO5 Institute, The University of Arizona, Tucson, AZ 85721, United States.
- Department of Immunobiology, The University of Arizona College of Medicine, Tucson, AZ 85724, United States.
- Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, United States.
- Department of Medicine, National Jewish Health, Denver, CO 80206, United States.
ORCID-Profile: Vadim Pivniouk, Mari Numata, Janko Ž Nikolich, Donata Vercelli
Förderung
- NIAID NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Pivniouk, V., Pivniouk, O., Uhrlaub, J. L., Hahn, S., Molzahn, A., Kimura, H., Numata, M., Chu, H. W., Ledford, J. G., Kraft, M., Nikolich, J. Ž., & Vercelli, D. (2025). IL-13 protects epithelial cells from SARS-CoV-2 infection by inhibiting ACE2-mediated virus binding and cell entry. ImmunoHorizons. https://doi.org/10.1093/immhor/vlaf056
Vancouver
Pivniouk V, Pivniouk O, Uhrlaub JL, Hahn S, Molzahn A, Kimura H, et al. IL-13 protects epithelial cells from SARS-CoV-2 infection by inhibiting ACE2-mediated virus binding and cell entry. ImmunoHorizons. 2025. doi:10.1093/immhor/vlaf056
BibTeX
@article{Pivniouk2025,
author = {Pivniouk, Vadim and Pivniouk, Oksana and Uhrlaub, Jennifer L and Hahn, Seongmin and Molzahn, Allyson and Kimura, Hiroki and Numata, Mari and Chu, Hong Wei and Ledford, Julie G and Kraft, Monica and Nikolich, Janko Ž and Vercelli, Donata},
title = {IL-13 protects epithelial cells from SARS-CoV-2 infection by inhibiting ACE2-mediated virus binding and cell entry},
journal = {ImmunoHorizons},
year = {2025},
doi = {10.1093/immhor/vlaf056}
}
EUVIMED